老年非瓣膜性房颤患者的衰弱、认知障碍与抗凝治疗
SAGE-AF队列纳入1244例65岁以上非瓣膜性房颤患者,14%衰弱、42%认知障碍、9%两者共存。衰弱与认知障碍共存与抑郁、高龄、低教育、非白人族裔、出血及卒中风险相关。抗凝处方与认知/衰弱状态无关,但两者共存者更多用DOAC,且报告较低治疗获益。
要点
- 老年NVAF患者中约半数存在衰弱或认知障碍,9%两者共存。
- 衰弱与认知障碍共存与抑郁、高龄、低教育、少数族裔及出血/卒中风险相关。
- 两者共存者更多使用DOAC而非VKA,且更可能报告较低治疗获益。
核心结论
- 在大型老年NVAF队列中,约半数患者存在衰弱或认知障碍,9%两者共存。
- 衰弱与认知障碍共存与抑郁、高龄、低教育、非西班牙裔白人以外的种族/族裔、出血风险及卒中风险相关。
- 抗凝处方与认知障碍和衰弱状态无关,但两者共存者更可能使用DOAC而非VKA,且更可能报告较低治疗获益。
研究设计与样本
- SAGE-AF研究队列(2016-2018年)纳入1244例65岁以上、符合OAC条件的非瓣膜性房颤患者。
- 评估工具包括Fried衰弱量表、蒙特利尔认知评估量表、PHQ-9、抗凝治疗受益量表等。
主要发现
- 患者平均年龄76岁(标准差7),49%为女性;14%衰弱,42%认知障碍,9%两者共存。
- 衰弱与认知障碍共存 versus 无两者:抑郁OR=4.62(95%CI 2.59-8.26),高龄OR=1.56(95%CI 1.29-1.88),低教育OR=3.81(95%CI 2.13-6.81),非西班牙裔白人以外的种族/族裔OR=7.94(95%CI 4.34-14.55),出血风险OR=1.43(95%CI 1.12-1.81),卒中风险OR=1.35(95%CI 1.13-1.62)。
- OAC处方与认知障碍和衰弱状态无关联;在85%服用OAC的患者中,两者共存者更可能使用DOAC而非VKA(OR=1.69;95%CI 1.01-2.80)。
- 两者共存(OR=1.87;95%CI 1.08-3.27)或认知障碍(OR=1.56;95%CI 1.09-2.24)与报告较低治疗获益的更高 odds 相关。
临床怎么用
- 对老年NVAF患者可考虑进行认知与躯体功能筛查,以识别可能从优化治疗中获益的高风险患者。
- 衰弱与认知障碍共存患者可能报告较低治疗获益,需关注其对治疗满意度和依从性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Oral anticoagulation (OAC) is challenging in older patients with nonvalvular atrial fibrillation (NVAF) who are often frail and have cognitive impairment. We examined the characteristics of older NVAF patients associated with higher odds of physical and cognitive impairments. We also examined if these high-risk patients have different OAC prescribing patterns and their satisfaction with treatment because it may impact optimal management of their NVAF. METHODS: The patients in the Systematic Assessment of Geriatric Elements in Atrial Fibrillation (SAGE-AF study cohort 2016-2018) had NVAF, were aged 65 and older, and eligible for the receipt of OAC. Measures included frailty (Fried Frailty scale), cognitive impairment (Montreal Cognitive Assessment Battery), OAC prescribing and type (direct oral anticoagulant [DOAC] or vitamin K antagonist [VKA]), depressive symptoms (Patient Health Questionnaire-9), bleeding, stroke risk, and treatment benefit (Anti-Clot Treatment Scale). RESULTS: Patients (n = 1,244) were 49% female, aged 76 (standard deviation = 7) years. A total of 14% were frail, and 42% had cognitive impairment. Frailty and cognitive impairment co-occurred in 9%. Odds of having both impairments versus none were higher with depression (odds ratio [OR] = 4.62; 95% confidence interval [CI] = 2.59-8.26), older age (OR = 1.56; 95% CI = 1.29-1.88), lower education (OR = 3.81; 95%CI = 2.13-6.81), race/ethnicity other than non-Hispanic White (OR = 7.94; 95% CI = 4.34-14.55), bleeding risk (OR = 1.43; 95% CI = 1.12-1.81), and stroke risk (OR = 1.35; 95% CI = 1.13-1.62). OAC prescribing was not associated with CI and frailty status. Among patients taking OACs (85%), those with both impairments were more likely to take DOAC than VKA (OR = 1.69; 95% CI = 1.01-2.80). Having both impairments (OR = 1.87; 95% CI = 1.08-3.27) or cognitive impairment (OR = 1.56; 95% CI = 1.09-2.24) was associated with higher odds of reporting lower treatment benefit. CONCLUSION: In a large cohort of older NVAF patients, half were frail or cognitively impaired, and 9% had both impairments. We highlight the characteristics of patients who may benefit from cognitive and physical function screenings to maximize treatment and enhance prognosis. Finally, the co-occurrence of impairment was associated with low perceived benefit of treatment that may impede optimal management.
引用
- Mailhot T, McManus DD, Waring ME, et al. Frailty, Cognitive Impairment, and Anticoagulation Among Older Adults with Nonvalvular Atrial Fibrillation. J Am Geriatr Soc. 2020. PMID: 32780497. doi:10.1111/jgs.16756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。